25 August 2021

Investor webinar: Full year results and update on Opin, the company's recently launched clinical trial recruitment platform: Monday 30th August 10.45am

Melbourne, Australia, Wednesday 25 August 2021, Opyl Limited (**ASX:OPL**) ("**Opyl**" or the "**Company**") announced today an investor webinar to deliver full year results and progress on its recently released clinical trial recruitment platform, Opin. Opin is the first of two novel AI platforms to be commercialised by Opyl, aimed at improving efficiency addressing the AUD$61bn global clinical trial market.

Investor update

Opyl CEO, Michelle Gallaher will deliver an online investor briefing where she will discuss Opyl's Q4 and FY21 results and progress with rolling out the Opin platform. The webinar is open to all; however, pre-registration is required.

Details of the webinar are:

Date: Monday 30th August 2021

Time: 10.45am Australian Eastern Standard Time

Registration: Webinar Ninja https://Opyl.webinarninja.com/live-webinars/6091588/register

Opin Update

"We're really pleased with the enthusiastic reception Opin is receiving from the medical research and clinical trials sector since launch", said Opyl CEO, Michelle Gallaher.

"As we predicted, there is strong interest in emerging digital approaches to improve patient recruitment for clinical trials. With more than 80% of trials failing to recruit on time or on budget[1], and recruitment making up on average 33% of the trial budget, the cost and time saving for biopharma and medtech companies can be in the hundreds of millions if not billions of dollars."

Since Opin launched in May 2021, several new and existing Opyl customers have signed up to the patient-led clinical trial recruitment service.

Opin is one of two novel AI-enabled clinical trial efficiency platforms developed by Opyl. The second platform, achieving proof of concept stage and approaching minimum viable product milestones, uses the emerging field of 'explainable' AI to model clinical trial protocols (plans) and predict the likelihood of clinical trials succeeding.

Opin combined with other Opyl platforms and AI tools not only help clinical trials recruit patients but can optimise clinical study design and implementation for improved clinical outcomes, and a better return on investment.

---

[1] Desai, M. Recruitment and retention of participants in clinical studies: Critical Issues and Challenges. Perspectives in Clinical Res. 2020 Apr-Jun; 11(2): 51–53

<u>What is Opin? (www.opin.ai)</u>

Opin.ai matches motivated patients to clinical trials, anywhere in the world. The proprietary platform uses artificial intelligence to search and rank a global trial database on the platform of more than 58,000 open trials and medical research studies that are searching for participants and healthy volunteers.

Poor recruitment is frequently cited as one of the core reasons for clinical trial failure[2]. More than 80% of clinical trials fail to recruit on time and on budget[3], putting at risk hundreds of millions, if not billions of dollars each year in delaying product to market or complete trial failure.

Opyl, based in Melbourne Australia, works at the intersection of artificial intelligence, social media and healthcare. It delivers market insights from social media data and improves the efficiency and value of the clinical research process by employing artificial intelligence and emerging digital tools.

The Board has authorised this announcement for release to the ASX.

-ENDS-

For media enquiries: Laura Blue   +61 416 699 925
For investor enquiries: info@opyl.ai
www.opyl.ai

Opyl is a new generation Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare design, development, and delivery.

Opyl works at the intersection of clinical trials, artificial intelligence, and social media.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment and retention solutions
- clinical trial predictive analytics
- deep social media insights

Our vision is to improve health and wellness by optimising data assets and digital activation to advance technologies for life.

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook

---

[2] Desai, M. Recruitment and retention of participants in clinical studies: Critical Issues and Challenges. Perspectives in Clinical Res. 2020 Apr-Jun; 11(2): 51–53

[3] Desai, M. Recruitment and retention of participants in clinical studies: Critical Issues and Challenges. Perspectives in Clinical Res. 2020 Apr-Jun; 11(2): 51–53